IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re F	Patent Application of:)	Group Art Unit: To Be Assigned
)	
NORN	MAN et al.)	Examiner: To Be Assigned
)	
Serial	No.: To Be Assigned)	Atty. Docket No.: GP141-03.UT
D11 - 4.	Name 12, 2002)	
rnea:	November 12, 2003)	
For:	ASSAY AND COMPOSITIONS)	
1 01.	FOR DETECTION OF)	
	BACILLUS ANTHRACIS)	
	NUCLEIC ACID)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)(1)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants bring to the Examiner's attention the references listed on the enclosed form PTO/SB/08 (two copies) for consideration in connection with the examination of the above-identified application. A copy of each of the cited references is enclosed.

In accordance with 37 C.F.R. § 1.97(b)(1), this Information Disclosure Statement is being submitted within three months of the certified filing date of the instant application.

Applicants respectfully request that the Examiner indicate consideration of the cited references by returning a copy of the enclosed form PTO/SB/08 with the Examiner's initials or other appropriate marks.

No fee is believed due in connection with this Information Disclosure Statement. If Applicants are mistaken, please charge the amount due to Deposit Account No. 07-0835 in the name of Gen-Probe Incorporated.

By:

Respectfully Submitted,

Date: November 12, 2003

Christine A. Gritzmacher
Registration Number 40,627

Agent for Applicants

GEN-PROBE INCORPORATED

Patent Department 10210 Genetic Center Drive San Diego, California 92121

PH: 858-410-8926 FAX: 858-410-8928

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known		
		Application Number	To Be Assigned	
		Filing Date	November 12, 2003	
		First Named Inventor	Sylvia A. Norman	
		Art Unit	To Be Assigned	
		Examiner Name	To Be Assigned	
heet	1 of 3	Attorney Docket Number	GP141-03.UT	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		^{US-} 5,591,631 A	01-07-1997	Leppla et al.	
		^{US-} 5,614,361 A	03-25-1997	Webster, Jr.	
		^{US-} 5,677,274 A	10-14-1997	Leppla et al.	
		^{US-} 5,840,312 A	11-24-1998	Mock et al.	
		^{US-} 5,874,046 A	02-23-1999	Megerle	
		^{US-} 6,087,104 A	07-11-2000	Yamada et al.	
		^{US-} 6,156,501 A	12-05-2000	McGall et al.	7.0
		^{US-} 6,448,016 B1	09-10-2002	Rastogi et al.	
		^{US-} 6,485,925 B1	11-26-2002	Duesbery et al.	
		^{US-} 20020042051 A1	04-11-2002	Wittwer	
		^{US-} 20020051791 A1	05-02-2002	Galloway et al.	
		^{US-} 20020055628 A1	05-09-2002	Keim et al.	
		^{US-} 20030170263 A1	09-11-2003	Williamson et al.	
		US-			
	1	US-			
	†	US-			

 	FORE	IGN PATENT DOCL	MENTS		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
	JP06253846 A	09-13-1994	Chisso Corp.		
	JP06253847 A	09-13-1994	Chisso Corp.		
	JP06261759 A	09-20-1994	Chisso Corp.		
	JP06261760 A	09-20-1994	Chisso Corp.		
	JP11004692 A	01-12-1999	Nippon Suisan		
	JP11004693 A	01-12-1999	Nippon Suisan		

Examiner Signature	Date Considered	
l • 1	Considered	_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

GP141-03.UT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** To Be Assigned Filing Date November 12, 2003 INFORMATION DISCLOSURE First Named Inventor Sylvia A. Norman STATEMENT BY APPLICANT Art Unit To Be Assigned (Use as many sheets as necessary) **Examiner Name** To Be Assigned

of 3

Sheet |2

Attorney Docket Number

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (# known)}			Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-			1	
		US-				
	ļ ————————————————————————————————————	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
<u> </u>		US-				
-		US-				
		US-				
		US-				
		US-	-			
	<u> </u>	US-	-			

Examiner Initials*	Cite No.1	ite Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
			10.05.0000		,	-
		WO 00/58505 A1	10-05-2000	 		┡
		WO 01/49823 A2	07-12-2001	Biosite Diagnos		Ł
		·				┞
						L

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Transtation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			C mpl te if Known		
			Applicati n Numb r	To Be Assigned	
INFOR	MATION DIS	CLOSURE	Filing Date	November 12, 2003	
STATEMENT BY APPLICANT			First Named Inventor	Sylvia A. Norman	
a	se as many sheets as n	nocecary)	Art Unit	To Be Assigned	
(USB as many sneets as necessary)			Examiner Name	To Be Assigned	
Sheet 3	of	3	Attorney Docket Number	GP141-03.UT	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROCHE MEDIA RELEASE, "New Rapid Anthrax Test developed through collaboration between Roche Diagnostics and Mayo Clinic", 5 Nov 2001, F. Hoffmann-LaRoche Ltd., Basel, CH.	
		FRIEDLANDER, "Anthrax", Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare, 1997, Ch. 22:467-478, Borden Inst., Walter Reed Army Med. Ctr.,US.	
		LEBLANC et al., "Less than One Hour Detection of Bacillus anthracis Spores and Vegetative Cells", (undated),p. 1-4,Infectio Diagnostic Inc., Quebec, CA.	,
		LITTLE et al., "Comparative Efficacy of Bacillus anthracis Live Spore Vaccine and Protective Antigen Vaccine", Infection & Immunity, May 1986;52(2):509-512, ASM, US.	
		SACCHI, et al., "Sequencing of 16S rRNA Gene: A Rapid Tool for Identification of Bacillus anthracis", Emerging Infectious Diseases, Oct 2002;8(10):1117-23, CDC, US.	
		CENTER FOR DISEASE CONTROL AND PREVENTION, "Summary of the Laboratory Response Network", 17 Apr 2002:1-2, CDC, US.	
		CENTER FOR DISEASE CONTROL AND PREVENTION, "Laboratory Response Network (LRN)", 24 Mar 2003:1-18, CDC, US.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.